Savara Inc SVRA
Institutional shares held
160 Million
14.3K
calls
24.9K
puts
Total value of holdings
$693M
$62K
calls
$108K
puts
Market Cap
$495M
114,043,000
Shares Out.
Institutional ownership
140.11%
# of Institutions
132
We take great care to ensure that the data presented and summarized in this overview for Savara Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SVRA
View all-
Nea Management Company, LLC Timonium, MD24.5MShares$106 Million5.38% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$76.4 Million19.88% of portfolio
-
Vr Adviser, LLC New York, NY12.7MShares$55 Million6.78% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$53.7 Million4.88% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$49.7 Million1.71% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT8.78MShares$38.1 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.31MShares$36.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.03MShares$34.9 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY7.96MShares$34.6 Million0.52% of portfolio
-
Vestal Point Capital, LP New York, NY4.02MShares$17.4 Million0.65% of portfolio
Latest Institutional Activity in SVRA
Top Purchases
Top Sells
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Insider Transactions at SVRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2025
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Direct |
23,629
-1.54%
|
-
|
|
Dec 09
2025
|
Richard J Hawkins |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.87%
|
-
|
|
Dec 09
2025
|
Joseph S Mc Cracken |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+11.74%
|
-
|
|
Dec 09
2025
|
David A Ramsay |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+1.54%
|
-
|
|
Dec 09
2025
|
Nevan C Elam |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+27.23%
|
-
|
|
Dec 09
2025
|
An Van Es Johansson |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+28.07%
|
-
|
|
Dec 04
2025
|
Yasmine Wasfi Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
21,992
-11.57%
|
$131,952
$6.37 P/Share
|
|
Dec 02
2025
|
Nevan C Elam |
SELL
Payment of exercise price or tax liability
|
Direct |
1,473
-2.15%
|
$7,365
$5.81 P/Share
|
|
Dec 02
2025
|
Nevan C Elam |
BUY
Exercise of conversion of derivative security
|
Direct |
5,860
+7.9%
|
$5,860
$1.46 P/Share
|
|
Nov 14
2025
|
Richard J Hawkins |
BUY
Exercise of conversion of derivative security
|
Direct |
5,860
+4.61%
|
$5,860
$1.46 P/Share
|
|
Oct 20
2025
|
Yasmine Wasfi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.56%
|
-
|
|
Jun 20
2025
|
Richard J Hawkins |
BUY
Open market or private purchase
|
Direct |
48,225
+29.46%
|
$96,450
$2.04 P/Share
|
|
May 29
2025
|
Joseph S Mc Cracken |
BUY
Open market or private purchase
|
Direct |
10,000
+3.69%
|
$20,000
$2.08 P/Share
|
|
Mar 31
2025
|
David A Ramsay |
BUY
Open market or private purchase
|
Direct |
150,000
+5.63%
|
$300,000
$2.77 P/Share
|
|
Feb 13
2025
|
Robert Matthew Lutz Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
38,263
-9.57%
|
$76,526
$2.83 P/Share
|
|
Dec 16
2024
|
David L Lowrance Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-6.16%
|
$75,000
$3.33 P/Share
|
|
Dec 16
2024
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
54,702
-3.44%
|
$164,106
$3.31 P/Share
|
|
Dec 16
2024
|
Richard J Hawkins |
SELL
Open market or private sale
|
Direct |
8,000
-10.63%
|
$24,000
$3.32 P/Share
|
|
Dec 13
2024
|
Anne Erickson Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,263
-4.03%
|
$54,789
$3.21 P/Share
|
|
Dec 13
2024
|
David L Lowrance Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,350
-5.66%
|
$73,050
$3.21 P/Share
|
Last 12 Months Summary
Buy / Acquisition
455K
Shares
From
11
Insiders
| Grant, award, or other acquisition | 235K shares |
|---|---|
| Open market or private purchase | 208K shares |
| Exercise of conversion of derivative security | 11.7K shares |
Sell / Disposition
173K
Shares
From
7
Insiders
| Payment of exercise price or tax liability | 61.7K shares |
|---|---|
| Open market or private sale | 87.7K shares |
| Bona fide gift | 23.6K shares |